E-Jet 3D-Printed Scaffolds as Sustained Multi-Drug Delivery Vehicles in Breast Cancer Therapy
- 118 Downloads
Combination chemotherapy is gradually receiving more attention because of its potential synergistic effect and reduced drug doses in clinical application. However, how to precisely control drug release dose and time using vehicles remains a challenge. This work developed an efficient drug delivery system to combat breast cancer, which can enhance drug effects despite reducing its concentration.
Controlled-release poly-lactic-co-glycolic acid (PLGA) scaffolds were fabricated by E-jet 3D printing to deliver doxorubicin (DOX) and cisplatin (CDDP) simultaneously.
This drug delivery system allowed the use of a reduced drug dosage resulting in a better effect on the human breast cancer cell apoptosis and inhibiting tumor growth, compared with the effect of each drug and the two drugs administrated without PLGA scaffolds. Our study suggested that DOX-CDDP-PLGA scaffolds could efficiently destroy MDA-MB-231 cells and restrain tumor growth.
The 3D printed PLGA scaffolds with their time-programmed drug release might be useful as a new multi-drug delivery vehicle in cancer therapy, which has a potential advantage in a long term tumor cure and prevention of tumor recurrence.
Key Wordscisplatin combination chemotherapy controlled release doxorubicin E-jet 3D printing
ACKNOWLEDGMENTS AND DISCLOSURES
This study was supported by National Natural Science Foundation of China (No. 31600782), Natural Science Foundation of Hunan Province (No. 2019JJ40018), Shenzhen Science and Technology Innovation Commission (No. JCYJ20170818112151323), and Hunan University (No. 53112102). The authors declare that they have no competing interests.
- 7.Massa E, Puzzoni M, Demurtas L, Cubeddu A, Pusole G, Dessì A, et al. E40Clinical outcome of patients with stage IV colorectal Cancer receiving combination chemotherapy without surgery as initial treatment. J Bryol. 2015.Google Scholar
- 11.Oliverasferraros C, Vazquezmartin A, Colomer R, De LR, Brunet J, Menendez JA. Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling. Int J Oncol. 2008;32(32):113–20.Google Scholar
- 27.Millet I, Bouicpages E, Hoa D, Azria D, Taourel P. Growth of breast cancer recurrences assessed by consecutive MRI. BMC Cancer. 2011;11(1):155–5.Google Scholar
- 33.K. Hirota, A.C. Doty, R. Ackermann, J. Zhou, K.F. Olsen, M.R. Feng, Y. Wang, S. Choi, W. Qu, A.S. Schwendeman, Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC development I: In vitro evaluation, Journal of Controlled Release Official Journal of the Controlled Release Society 244 (2016).PubMedCrossRefPubMedCentralGoogle Scholar
- 37.Gyan E, Foussard C, Bertrand P, Michenet P, Le GS, Berthou C, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113(5):995–1001.PubMedCrossRefPubMedCentralGoogle Scholar
- 40.Shanmugam V, Chien YH, Cheng YS, Liu TY, Huang CC, Su CH, et al. Oligonucleotides--assembled au nanorod-assisted cancer photothermal ablation and combination chemotherapy with targeted dual-drug delivery of doxorubicin and cisplatin prodrug. ACS Appl Mater Interfaces. 2014;6(6):4382–93.CrossRefGoogle Scholar